Originally published Wednesday, April 2, 2008 at 12:00 AM
2 AIDS drugs tied to heart risk
A commonly used AIDS drug appears to nearly double the risk of a heart attack, researchers said Tuesday. In a study published online by...
The Associated Press
LONDON — A commonly used AIDS drug appears to nearly double the risk of a heart attack, researchers said Tuesday.
In a study published online by the medical journal Lancet, the researchers also said another, less frequently used AIDS drug increased the chances of a heart attack by 50 percent. Experts said doctors should be aware of the increased risks, but they did not recommend that patients abandon the two drugs, Ziagen and Videx.
AIDS drugs "are wonderful and lifesaving, but they do have toxicity problems," said Dr. Charlie Gilks, an AIDS treatment expert at the World Health Organization. "It may be that we can continue to use them, but we need to be aware of their long-term problems."
AIDS drugs are used in combination, so they could be swapped with others if necessary.
Experts have suspected that AIDS drugs could cause heart problems, but no definitive evidence has been available. The drugs come with many side effects, including liver and kidney failure, chronic fatigue syndrome, hepatitis and jaundice.
Jens D. Lundgren of the University of Copenhagen and colleagues analyzed data from more than 33,000 people infected with the AIDS virus in Europe, the United States and Australia to study the long-term effects of five AIDS drugs. The patients were followed for up to five years to see who had heart problems.
In the 754 patients who had heart attacks, 192 had recently taken Ziagen, also known as abacavir, and 124 had recently taken Videx, also known as didanosine.
Those who took Ziagen, included in many AIDS regimens worldwide, had twice the chances of a heart attack compared with patients on other AIDS drugs, the researchers reported. Those on Videx had a 50 percent higher chance. But the risk disappeared six months after patients stopped taking the drugs.
Lundgren said patients already susceptible to heart problems were most at risk.
No increased heart-attack risk was found for patients on the other drugs in the study, zidovudine (AZT), stavudine (Zerit) or lamivudine (Epivir). The medications all block an enzyme that the AIDS virus needs to multiply.
The research was funded by the European Medicines Agency, a regulatory group, which solicited contributions from makers of AIDS drugs for studies on their long-term effects.
Copyright © 2008 The Seattle Times Company
On the left hand, answers aren't easy
Getting active outside can bring sunshine to your winter
How to encourage healthy computing
Obese people asked to eat fast food for health study
Charlie Sheen claims AA has a 5 percent success rate — is he right?

- Lakewood cop accused of embezzling $150K meant for slain officers' families
- 3 big health insurers stockpile $2.4 billion as rates keep rising
- Agency set to investigate handling of 911 call about Josh Powell
- Quick decisions: How Washington hired its new football staff
- Historic day for gay marriage as another fight looms
- Justin Wilcox's versatile defensive style is the right fit for Huskies | Jerry Brewer
- Social worker recounts minutes before Powell fire
- It's Terrence Time: Enigmatic Ross leads Huskies
- $25B settlement reached over foreclosure abuses
- Club promoter convicted in brutal 2010 murder of Des Moines prostitute
- State Medicaid program to stop paying for unneeded ER visits
- 3 big health insurers stockpile $2.4 billion as rates keep rising
- Wanted in Seattle classrooms: more teachers of color
- One man's audacious pursuit of sailing history
- Economy, blogs give survivalists new reason to look to Northwest
- Darren Berg gets 18-year sentence for Ponzi scheme
- State's share of mortgage settlement: $648 million
- $25B settlement reached over foreclosure abuses
- Bellevue College adds a third bachelor's degree program
- 'Gauguin and Polynesia': dazzling mix-and-match | Art review
